The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE
Abstract
Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors. Amifostine, a broad-spectrum cytoprotector of normal tissues, has been approved by U.S. Food and Drug Administration for use in patients receiving cisplatin. Such administration of amifostine has been reported to reduce cisplatin-related toxicities in some studies, but not all. The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · Cited by 212
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.574 · Cited by 192
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner, B. H., LaQuaglia, M. P., Bonilla, M. A., Lindsley, K., Rosenfield, N., Yeh, S., Eddy, J., Gerald, W. L., Heller, G., & Cheung, N. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2607 · Cited by 174
Neuroprotectant drugs in cisplatin neurotoxicity.
Cavaletti, G., Cascinu, S., Venturino, P., Tedeschi, M., & Tredici, G. (1996) · PubMed · Cited by 24
Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green, D., Bensely, D., & Schein, P. S. (1994) · PubMed · Cited by 18
Amifostine: potential for clinically useful cytoprotection
Budd, G. T., Lorenzi, V., Ganapathi, R. N., Adelstein, D. J., Pelley, R. J., Olencki, T. E., McLain, D., & Bukowski, R. M. (1994) · Supportive Care in Cancer · doi:10.1007/bf00344052 · Cited by 13
Cited by
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
Mechanisms of cisplatin-induced ototoxicity and prevention
Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007) · Hearing Research · doi:10.1016/j.heares.2006.09.015 · Cited by 563
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies
Rybak, L. P., Mukherjea, D., Jajoo, S., & Ramkumar, V. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.219.177 · Cited by 372
Metadata
- Authors
- Sastry, J., & Kellie, S. J.
- Venue
- Pediatric Hematology and Oncology
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 22
- Issue
- 5
- Pages
- 441-445
- ISSN
- 0888-0018 (ISSN-L)
- 1521-0669
- OpenAlex
- W2059068055
- Cited by
- 258
- References
- 7
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE. https://app.cochat.ai/papers/10.1080/08880010590964381
- The paper
- Sastry, J., & Kellie, S. J. (2005). SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE. Pediatric Hematology and Oncology. https://doi.org/10.1080/08880010590964381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.